scispace - formally typeset
A

Ahmedin Jemal

Researcher at American Cancer Society

Publications -  568
Citations -  492750

Ahmedin Jemal is an academic researcher from American Cancer Society. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 132, co-authored 500 publications receiving 380474 citations. Previous affiliations of Ahmedin Jemal include Centers for Disease Control and Prevention & Emory University.

Papers
More filters
Journal ArticleDOI

Economic loss attributable to cigarette smoking in the USA: an economic modelling study.

TL;DR: In this paper , the authors used a dynamic macroeconomic model of personal income per capita at the state level to estimate the state-specific, annual, avoidable economic loss attributable to cigarette smoking in 2020 under the counterfactual 5% prevalence of cigarette smoking.
Journal ArticleDOI

Reaching 80% human papillomavirus vaccination prevalence by 2026: How many adolescents need to be vaccinated and what are their characteristics?

TL;DR: The number of additional adolescents (11‐12 years old) who need HPVV for 80% prevalence to be reached by 2026 is estimated.
Journal ArticleDOI

Adequacy of Pathologic Reports of Invasive Breast Cancer From Mastectomy Specimens at Tikur Anbessa Specialized Hospital Oncology Center in Ethiopia.

TL;DR: No systematic evidence exists regarding the adequacy of breast pathology reporting in Ethiopia and quality measurement and improvement programs and capacity-building interventions by national pathology and oncology organizations, collaboration with medical and public health organizations in neighboring countries, adoption of synoptic reporting templates, use of electronic pathology reporting, and histotechnology and histopathology training collaborations with laboratories in high-resource regions are recommended.
Journal ArticleDOI

Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018

TL;DR: The findings of this study suggest that PBT uptake varies by indication group and is most commonly used to treat cancers for which PBT effectiveness is still under study.